Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-06-29 02:02 UTC

BIOMED PULSE

Monday, June 29, 2026 | Your daily briefing on longevity, viruses, and new cures

⚡ TL;DR

The Bundibugyo virus Ebola PHEIC in DRC and Uganda now stands at 896 confirmed cases and 232 deaths as of June 17, and the joint Africa CDC/WHO response plan needs $518 million — this is the dominant global health emergency right now. Mood: urgent on Ebola, watchful on hantavirus, cautiously optimistic on a delirium-dementia aging link that could reshape how we treat hospital patients.

🦠 OUTBREAKS & VIRUSES

EBOLA BUNDIBUGYO VIRUS — DRC AND UGANDA (PHEIC)

  • As of June 17, 2026, 896 confirmed cases and 232 deaths have been reported from DRC, with cross-border transmission ongoing in Uganda. [1]
  • WHO declared a public health emergency of international concern (PHEIC) on May 17, 2026, centered on Ituri Province, Mongbwalu Health Zone; WHO's IHR Emergency Committee confirmed PHEIC status but said the event does not yet meet criteria for pandemic emergency. [2] [3]
  • Africa CDC and WHO launched a joint continental preparedness and response plan on June 5, 2026, targeting US$ 518 million to support African countries in surveillance, response, and containment. [4]
  • WHO released its first comprehensive clinical management guidelines for filovirus disease (covering all Ebola subtypes and Marburg) on June 17, 2026, timed directly to the outbreak. [5]
  • WHO convened expert advisory groups on May 28, 2026 to assess candidate vaccines and therapeutics specifically against Bundibugyo virus, for which no pre-approved countermeasures exist. [6]
  • CDC issued Ebola updates through June 26, 2026, with enhanced airport screening already operating at Washington-Dulles International Airport and Atlanta Hartsfield-Jackson. [7] [8] [9]

HANTAVIRUS — M/V HONDIUS CRUISE SHIP, MULTI-COUNTRY

  • The Andes hantavirus outbreak linked to cruise ship M/V Hondius, first reported May 2, 2026, has generated four WHO Disease Outbreak News reports; as of the fourth DON (May 28, 2026), additional confirmed cases have been identified beyond the original seven cases from 23 countries. [10]
  • WHO Director-General issued a personal message to the people of Tenerife on May 14 thanking them for cooperation in safely disembarking more than 120 passengers amid the outbreak.
  • CDC provided a hantavirus response transcript update as recently as June 24, 2026, signaling the situation remains under active monitoring.

NIPAH VIRUS — INDIA (KERALA) AND BANGLADESH

  • On June 11, 2026, Kerala State confirmed one laboratory-confirmed Nipah virus (NiV) case in Kozhikode district, an adult male with neurological symptoms hospitalized June 10; contact tracing is ongoing.
  • Earlier in 2026, two healthcare worker NiV cases were confirmed in West Bengal's Barasat hospital (January) and one case in Bangladesh's Rajshahi Division (February), indicating continued endemic circulation.

YELLOW FEVER — AMERICAS AND AFRICA

  • WHO's June 24 global update reports that from January 1 to May 26, 2026, six countries reported 79 human yellow fever infections; transmission activity in the Americas that surged in 2025 has persisted into 2026.

MERS-COV — GLOBAL

  • As of December 21, 2025, 19 MERS-CoV cases including four deaths were reported globally in 2025, with 17 from Saudi Arabia and two from France — low count but persistent endemicity.

MPOX — RECOMBINANT CLADE IB/IIB STRAIN

  • WHO's February 14, 2026 DON documented two cases of a recombinant monkeypox virus strain combining genomic elements of clades Ib and IIb, a natural but concerning viral evolution event that could affect immune protection.

MEASLES — BANGLADESH AND GLOBAL CONTEXT

  • Bangladesh notified WHO on April 4, 2026 of 19,161 suspected measles cases and 2,897 laboratory-confirmed cases across 58 of 64 districts; global measles cases reached 10.3 million in 2023 with continued surge signaling.

SALMONELLA — MULTIPLE ACTIVE OUTBREAKS (U.S.)

  • CDC is actively tracking Salmonella outbreaks linked to backyard poultry (34 sick across 13 states, with a prior update showing 150 more cases, over one-quarter in children under 5), whole cucumbers, and pet veiled chameleons (all cases in children 2 years or younger).
  • Extensively drug-resistant Salmonella linked to moringa leaf powder capsules has resulted in hospitalizations across 28 states (65 total cases as of January 29, 2026), with the outbreak still growing as of May 27, 2026.

LISTERIA — REQUESÓN/SOFT RICOTTA CHEESE (U.S.)

  • CDC warned on June 5, 2026 of a Listeria outbreak linked to requesón/soft ricotta cheese, following a string of Listeria outbreaks in 2025-2026 tied to prepared meals, deli meats, and supplement shakes.

NEW WORLD SCREWWORM

  • CDC activated its Emergency Operations Center for a New World Screwworm response on June 12, 2026 — a parasitic fly whose larvae infest living tissue in humans and animals.

INFANT BOTULISM — POWDERED INFANT FORMULA

  • CDC updated its infant botulism investigation on June 13, 2026, urging parents to immediately stop using all Nara Organics Whole Milk Organic Infant Formula after linking the product to confirmed cases.

AVIAN INFLUENZA A(H9N2) — ITALY

  • Italy notified WHO on March 21, 2026 of one human H9N2 case in an adult male returning from Senegal, confirmed by next-generation sequencing; human-to-human transmission not established.

🧬 LONGEVITY & AGING

DELIRIUM AS MISSING LINK BETWEEN INFECTION AND DEMENTIA

  • Two commentaries in Lancet Healthy Longevity (Sipilä/Kivimäki and Penfold/Jiwaji/MacLullich, both June 2026) examine whether delirium — the acute confusion that often follows severe infection or surgery in older adults — may be a causal pathway to subsequent dementia, not just a symptom marker.
  • The implication is mechanistic: delirium could represent neuroinflammatory injury that accelerates neurodegenerative cascades, meaning aggressive prevention and treatment of delirium in hospitals may also delay dementia onset.

INSULIN RESISTANCE AND MILD COGNITIVE IMPAIRMENT IN AGING

  • A Scandinavian Journal of Primary Health Care study (Rotonen et al., June 23, 2026) found an association between insulin resistance and mild cognitive impairment (MCI) in aging populations, reinforcing the metabolic-brain axis as a target for longevity interventions.

GUT-DERIVED UREMIC TOXINS AND CARDIORENAL AGING

  • Xu, Snelson, and Marques in Gut Microbes (June 15, 2026) examine cardiovascular-kidney-metabolic syndrome through the lens of gut-derived uremic toxins — waste compounds produced by gut bacteria that accumulate when kidneys decline, linking microbiome aging to multi-organ disease.

MUSCLE NUCLEUS AS A MECHANOBIOLOGICAL HUB IN AGING

  • Esen et al. in Nucleus (June 18, 2026) describe how the cell nucleus in muscle fibers acts as a physical mechanosensor, with nuclear architecture changes in aging muscle potentially driving the loss of muscle mass and function seen in sarcopenia.

SENESCENCE-INDEPENDENT DEDIFFERENTIATION IN CARTILAGE CELLS

  • Alemujiang et al. in Regenerative Therapy (June 13, 2026) identified a conserved nine-gene module in long-term expandable auricular chondrocytes that drives dedifferentiation — the loss of specialized cell identity — independently of cellular senescence, suggesting new targets for cartilage regeneration therapies.

MULTIPLE LONG-TERM CONDITIONS AND KIDNEY DISEASE OUTCOMES

  • The NURTuRE-CKD multicentre cohort study (Boateng et al., Ann Med, June 23, 2026) found that having multiple long-term conditions significantly accelerates mortality, progression to kidney failure, and reduced quality of life in people with chronic kidney disease — quantifying what clinicians call the multimorbidity burden.

BIOFILM AND GUT FITNESS: PROBIOTIC LONGEVITY ANGLE

  • Kunyeit and Rao in Gut Microbes (June 21, 2026) found that biofilm overproduction in Bacillus subtilis enhances gastrointestinal stress tolerance and intestinal fitness, relevant to research on probiotic bacteria that could support gut resilience in aging populations.

💊 NEW CURES & APPROVALS

KEYTRUDA (PEMBROLIZUMAB) — MERCK SHARP AND DOHME

  • Merck's anti-PD-1 checkpoint inhibitor pembrolizumab (Keytruda, BLA125514) received a supplemental approval, expanding its indications; pembrolizumab blocks the PD-1 receptor on T-cells to restore anti-tumor immune activity.

KEYTRUDA QLEX (PEMBROLIZUMAB + BERAHYALURONIDASE ALFA) — MERCK SHARP AND DOHME

  • A separate supplemental approval was issued for Keytruda Qlex (BLA761467), a subcutaneous formulation combining pembrolizumab with berahyaluronidase alfa-pmph, an enzyme that degrades hyaluronic acid in tissue to allow subcutaneous delivery of the full antibody dose — removing the need for intravenous infusion.

TRODELVY (SACITUZUMAB GOVITECAN-HZIY) — IMMUNOMEDICS INC

  • Trodelvy (BLA761115) received a supplemental approval; it is an antibody-drug conjugate (ADC) linking an anti-Trop-2 antibody to the topoisomerase inhibitor SN-38, used in metastatic cancers including triple-negative breast cancer and urothelial carcinoma.

IBRANCE (PALBOCICLIB) — PFIZER

  • Pfizer's CDK4/6 inhibitor palbociclib (Ibrance) received supplemental approvals under both NDA212436 and NDA207103; CDK4/6 inhibitors block tumor cell division and are used in hormone receptor-positive, HER2-negative breast cancer.

TRYNGOLZA AUTOINJECTOR (OLEZARSEN SODIUM) — IONIS PHARMACEUTICALS

  • Ionis received a supplemental approval for the autoinjector formulation of olezarsen sodium (NDA218614), an antisense oligonucleotide (ASO) targeting APOC3 messenger RNA to reduce triglyceride levels in familial chylomicronemia syndrome and severe hypertriglyceridemia.

SPRAVATO (ESKETAMINE HYDROCHLORIDE) — JANSSEN PHARMACEUTICALS

  • Janssen's esketamine nasal spray (NDA211243) received a supplemental approval; esketamine is an NMDA receptor antagonist approved for treatment-resistant depression and major depressive disorder with acute suicidal ideation.

RINVOQ LQ (UPADACITINIB) — ABBVIE

  • AbbVie received a supplemental approval for Rinvoq LQ (NDA218347), a liquid formulation of the JAK1-selective inhibitor upadacitinib, expanding access for patients who cannot swallow tablets — relevant to pediatric and elderly populations with rheumatoid arthritis, atopic dermatitis, or inflammatory bowel disease.

PROLIA (DENOSUMAB) — AMGEN

  • Amgen's Prolia (BLA125320, denosumab) received a supplemental approval; denosumab is a RANK-L inhibitor used in postmenopausal osteoporosis and bone loss conditions, with direct relevance to skeletal aging.

RIFAPENTINE — MACLEODS PHARMACEUTICALS

  • A generic rifapentine (ANDA217042) received original approval from Macleods Pharmaceuticals; rifapentine is a rifamycin antibiotic used in tuberculosis treatment, including shorter-course latent TB regimens.

🧪 CLINICAL TRIALS

ALZHEIMER'S DISEASE — TABLET-BASED REMOTE COGNITIVE TRAINING (NCT07521865)

  • A trial adapting a tablet-based cognitive training program for older adults with Mild Cognitive Impairment (MCI) and early Alzheimer's disease is assessing feasibility, acceptability, and usability of remote delivery — targeting specific cognitive components that decline earliest.

FOSTAMATINIB IN LUNG TRANSPLANT WITH DONOR-SPECIFIC ANTIBODIES (NCT06948097)

  • The SIMILAR trial (Syk Inhibition in Mitigating Lung Allograft Rejection) is evaluating fostamatinib — a Syk kinase inhibitor — for safety and tolerability in lung transplant recipients who develop donor-specific antibodies, an antibody-mediated rejection mechanism that limits median lung transplant survival to 6-7 years.

MRNA-1345 AND MRNA-1365 (RSV/HMPV VACCINE) IN INFANTS 5 MONTHS TO UNDER 24 MONTHS (NCT05743881)

  • This safety and immunogenicity trial tests Moderna's mRNA-1365 (targeting RSV and human metapneumovirus) and mRNA-1345 (RSV alone) in very young children aged 5 months to under 24 months, an age group at highest risk of severe respiratory disease.

KETOCONAZOLE FOR MILD AUTONOMOUS CORTISOL SECRETION (NCT07649317)

  • An NIH trial is examining whether ketoconazole, a steroidogenesis inhibitor, can normalize the disrupted daily cortisol rhythm in patients with mild autonomous cortisol secretion (MACS) — a condition driving hypertension, diabetes, and weight gain through excess adrenal cortisol output.

NEOADJUVANT INHALED AZACYTIDINE PLUS DURVALUMAB FOR EARLY NSCLC — AZA-AEGEAN (NCT06694454)

  • This trial combines inhaled azacytidine (a DNA methyltransferase inhibitor for epigenetic reprogramming) with platinum-based chemotherapy and durvalumab (anti-PD-L1) before surgery in resectable early-stage non-small cell lung cancer, testing whether epigenetic priming enhances immunotherapy response.

DUAL VS TRIPLE LIPID-LOWERING THERAPY IN TYPE 2 DIABETES WITH ELEVATED LDL (NCT07255820)

  • An open-label RCT is comparing dual therapy (rosuvastatin plus ezetimibe) versus triple therapy (adding bempedoic acid) in type 2 diabetes patients with elevated LDL cholesterol, testing the cardiovascular benefit of ATP-citrate lyase inhibition on top of standard care.

INTRANASAL SARS-COV-2 VACCINE OCU500 (CHAD36 VECTOR) IN PREVIOUSLY VACCINATED ADULTS (NCT07536308)

  • A Phase 1 dose-escalation trial is testing OCU500, a ChAd36 adenoviral vector encoding SARS-CoV-2 spike protein, delivered intranasally and by inhalation in adults aged 18-64 who already completed a primary COVID-19 series and at least one booster — targeting mucosal immunity not induced by injected vaccines.

PFSPZ-LARC2 GENETICALLY ATTENUATED MALARIA SPOROZOITE VACCINE — PHASE 1 (NCT06735209)

  • A first-in-human, randomized double-blind placebo-controlled Phase 1 trial of PfSPZ-LARC2, a live-attenuated Plasmodium falciparum sporozoite malaria vaccine, is enrolling up to 22 malaria-naive adults to test safety, immunogenicity, and efficacy.

📢 PUBLIC HEALTH

CDC ACIP JUNE 25-26, 2026 MEETING CONCLUDED WITH JOINT STATEMENT

  • CDC's Advisory Committee on Immunization Practices (ACIP) met June 25-26, 2025 and issued a joint statement; the agenda and presentations have been posted online — details of specific votes are expected to follow.

WHO: UNSAFE FOOD CAUSES 866 MILLION ILLNESSES AND 1.5 MILLION DEATHS ANNUALLY

  • New WHO estimates released June 4, 2026 show 866 million food-borne illnesses and 1.5 million deaths each year globally; children under five face nearly three times the illness risk compared to older children and adults.

GLOBAL HEALTH PROGRESS SLOWING OR REVERSING — WHO WORLD HEALTH STATISTICS 2026

  • WHO's World Health Statistics 2026 report (May 13, 2026) finds progress on global health targets is uneven, slowing, and in some areas reversing, citing widening gaps in health system capacity and disease burden.

CDC DRUG OVERDOSE DEATHS DECLINE 27 PERCENT

  • CDC's National Vital Statistics System data show a 27% decrease in U.S. drug overdose deaths in 2024, building on a 24% decline reported in 2025 — the largest consecutive two-year decline on record.

CDC WORLD CUP 2026 ACTIVATION AND EBOLA SCREENING

  • CDC confirmed it has activated World Cup 2026 health surveillance protocols alongside its Ebola airport screening expansion, monitoring travelers at Washington-Dulles and Atlanta for febrile illness given the ongoing DRC/Uganda PHEIC. [9] [8]

DRUG-RESISTANT BACTERIA SHARP RISE — CDC REPORT (SEPTEMBER 2025)

  • A CDC report from September 23, 2025 documented a dramatic increase in dangerous drug-resistant bacteria, reinforcing antimicrobial resistance as an escalating background threat to all clinical care.

U.S. COMPLETED WHO WITHDRAWAL — JANUARY 22, 2026

  • The United States formally completed its withdrawal from WHO on January 22, 2026, citing COVID-19 failures and politicization; the U.S. is now operating through bilateral health cooperation arrangements, affecting global outbreak information-sharing architecture.

This briefing is for informational purposes only and does not constitute medical advice. Always consult qualified healthcare professionals for personal medical decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo & Uganda — WHO Disease Outbreak News
  2. Epidemic of Ebola Disease caused by Bundibugyo virus in the Democratic Republic of the Congo and Uganda determined a pub — WHO News
  3. First meeting of the IHR Emergency Committee regarding the epidemic of Ebola Bundibugyo virus disease in the Democratic — WHO News
  4. Africa CDC and WHO launch joint continental Ebola response plan — WHO News
  5. WHO issues comprehensive guidelines on filovirus disease, including Ebola and Marburg disease — WHO News
  6. Experts convened by WHO advise on candidate treatments and vaccines for Ebola disease caused by Bundibugyo virus — WHO News
  7. Transcript - Update on Ebola Outbreak in the Democratic Republic of the Congo and Uganda: 6/26/26 — CDC Newsroom
  8. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  9. Enhanced Ebola Airport Screening Begins at Washington-Dulles International Airport — CDC Newsroom
  10. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260629-02-v15 · 2026-06-29 02:02 UTC

Read next